Medicaid does pay for testosterone replacement therapy, but only when your provider documents that it is medically necessary for a diagnosed condition and gets the prescription through prior authorization. Every state Medicaid program covers prescription drugs, and testosterone is on the covered list, yet almost every state also flags it for review before a pharmacy can fill it.1Medicaid.gov. Mandatory and Optional Medicaid Benefits What you actually get depends on your diagnosis, your lab results, the formulation your provider prescribes, and the rules of the state you live in.
What Counts as a Covered Medical Reason
Medicaid uses medical necessity as the gate. A treatment qualifies when it is reasonable and appropriate for a diagnosed illness, consistent with accepted clinical standards. Testosterone clears that bar when it treats a recognized condition. It does not clear it when the purpose is anti-aging, athletic performance, or general wellness.
The FDA has approved testosterone products only for men whose low testosterone is tied to a specific medical cause, such as a genetic condition, chemotherapy damage to the testes, or a problem with the pituitary gland or hypothalamus. Products are not approved for men whose testosterone is simply low without an identified underlying cause.2U.S. Food and Drug Administration. Testosterone Information State Medicaid programs generally track that distinction. If your provider cannot point to a diagnosed condition causing the deficiency, approval is unlikely.
The Labs and Symptoms Your Provider Has to Document
Most Medicaid programs follow the American Urological Association’s guideline, which sets a total testosterone level below 300 ng/dL as the diagnostic threshold for testosterone deficiency.3American Urological Association. Evaluation and Management of Testosterone Deficiency AUA Guideline One low reading is not enough. You will typically need two separate early-morning blood draws on different days, both below 300 ng/dL. Morning matters because testosterone peaks in the early hours and drops later in the day, so an afternoon sample can come back misleadingly low.
Lab numbers by themselves also don’t seal the case. You need clinical symptoms that fit hypogonadism: persistent fatigue, reduced sex drive, loss of muscle mass, erectile dysfunction. Reviewers look for both the lab confirmation and the symptom picture. Expect additional bloodwork before treatment starts, including a baseline hematocrit and a prostate-specific antigen test, because testosterone can raise red blood cell counts and has implications for prostate health.
How Prior Authorization Works
Prior authorization is the single biggest hurdle between a prescription and a filled bottle. Your provider submits a request to your state Medicaid agency or managed care plan with the lab results, diagnosis, symptoms, and treatment plan. Incomplete requests are the most common reason for delays, so the documentation needs to be thorough the first time.
Federal law requires Medicaid programs to respond to prior authorization requests for prescription drugs within 24 hours and to dispense at least a 72-hour emergency supply while the request is pending.4Office of the Law Revision Counsel. 42 USC 1396r-8 – Payment for Covered Outpatient Drugs That clock applies to both fee-for-service Medicaid and managed care organizations. An approval typically specifies the formulation, dosage, and duration, and usually runs up to 12 months before you have to reauthorize.
Which Forms of Testosterone Get Covered
Each state Medicaid program maintains a preferred drug list that ranks covered medications by cost-effectiveness, and that list largely dictates which formulation you can get without a fight. The common options:
- Intramuscular injections. Testosterone cypionate and testosterone enanthate are injected into muscle every one to two weeks. Generic cypionate is the cheapest option by a wide margin and lands on most states’ preferred drug lists.
- Topical gels applied daily to the skin. Brand-name gels can cost roughly ten times more than generic injections, though generic gel versions have narrowed the gap and some states list them as preferred.
- Transdermal patches worn on the skin and replaced daily. Less commonly covered as a preferred option.
- Subcutaneous pellets, nasal gels, buccal tablets, and oral capsules. These exist but are less commonly covered and often require extra justification.
If your provider prescribes a non-preferred formulation, such as a brand-name auto-injector when generic cypionate vials are preferred, the program will generally require evidence that you tried and failed the preferred options first. This step-therapy requirement is where many prior authorization requests stall. If there is a clinical reason you cannot use the preferred form, like documented needle phobia or a skin reaction to gels, your provider can submit that reasoning, but approval is not automatic.
What You’ll Pay at the Pharmacy
If your prior authorization is approved, your actual out-of-pocket cost is usually minimal. Federal law caps Medicaid copayments for preferred prescription drugs at a few dollars per fill, and many states set copays even lower or waive them entirely for certain populations, including people with incomes below the poverty line. Non-preferred drugs carry slightly higher copays but are still capped by federal statute.
The real cost difference shows up in which formulation you use. Generic testosterone cypionate injections are among the least expensive prescription medications on the market. Topical gels and brand-name products cost substantially more, and while Medicaid absorbs most of that cost, your copay tier may be higher for non-preferred formulations. Working with your provider to use a preferred generic injection, when it’s clinically appropriate, keeps your cost as low as possible.
Testosterone as Gender-Affirming Care
If you are seeking testosterone as part of gender-affirming care rather than for diagnosed hypogonadism, coverage is far less uniform. Roughly half of states plus the District of Columbia permit Medicaid coverage of gender-affirming hormone therapy. Approximately ten states have enacted policies explicitly prohibiting Medicaid from covering gender-affirming care for both adults and minors, and a handful of additional states restrict coverage for minors only. The remaining states have no explicit policy, which pushes decisions to individual managed care plans or case-by-case medical necessity reviews.
At the federal level, Section 1557 of the Affordable Care Act prohibits sex discrimination in federally funded health programs, and prior federal guidance interpreted that to include gender identity. In February 2025, the Department of Health and Human Services rescinded that guidance, citing federal court decisions that questioned whether Section 1557’s prohibition on sex discrimination extends to gender identity.5U.S. Department of Health and Human Services. Rescission of HHS Notice and Guidance on Gender Affirming Care Civil Rights and Patient Privacy The practical effect is that federal enforcement of nondiscrimination protections for gender-affirming care is not currently active, and coverage turns almost entirely on state policy.
Your first step is checking whether your state Medicaid program covers it at all. In states that do, the medical necessity documentation looks similar to what’s required for hypogonadism, though the diagnostic codes and supporting records differ. In states with explicit bans, Medicaid will not cover the prescription regardless of the medical necessity argument.
Reauthorization and Ongoing Monitoring
Approval the first time isn’t permanent. Most Medicaid programs authorize testosterone therapy for a maximum of 12 months before requiring reauthorization. Renewal typically requires updated lab work showing that your testosterone levels remain within or below the normal male range on your current dose, plus documentation that therapy is still clinically needed.
The monitoring serves a real medical purpose. Testosterone can increase hematocrit, which raises the risk of blood clots if levels climb too high, so most programs require periodic hematocrit checks along with follow-up testosterone levels. Prostate-specific antigen monitoring is also standard, particularly for older patients. If your follow-up labs show testosterone above the normal male range, expect a dose adjustment before reauthorization is granted. Programs want to see the minimum effective dose, not supraphysiologic levels.
What to Do if Your Claim Is Denied
A denial is not the end. Medicaid beneficiaries have appeal rights built into federal law, and a meaningful share of initial denials get overturned, especially when the original submission was missing documentation the provider can now supply.
If you’re enrolled in a Medicaid managed care plan, the process runs in two stages. You have 60 calendar days from the denial notice to file an internal appeal with your plan, in writing or orally. The plan must resolve standard appeals within 30 days, or within 72 hours for urgent cases. If the plan upholds the denial, you can request an independent state fair hearing, with 90 to 120 calendar days from the plan’s resolution notice to make the request. The state must issue a final decision within 90 days of when you originally filed with your managed care plan.6MACPAC. Chapter 2 Denials and Appeals in Medicaid Managed Care
For traditional fee-for-service Medicaid, you can request a state fair hearing directly. Federal regulations give you up to 90 days from the date the denial notice is mailed to submit the request.7eCFR. Subpart E Fair Hearings for Applicants and Beneficiaries
One deadline is easy to miss. If your managed care plan is terminating, reducing, or suspending testosterone therapy that was previously authorized, you can request that benefits continue during the appeal, but you have to make that request within 10 days of the denial notice or before the denial takes effect, whichever is later. Miss that window and your coverage stops while the appeal plays out.